Physician profile
Michael Strobel
NPI 1356828420
$1,694.19
in general payments reported to CMS, 2019-2025
20 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $307 · 2022: $566 · 2023: $146 · 2024: $336 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $821.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $503.50 | 2021-2023 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $186.01 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $177.83 | 2021-2025 | Farxiga |
| Pfizer INC. | $169.62 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $109.73 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.42 | 2023-2025 | Jardiance |
| Inspire Medical Systems, INC. | $57.17 | 2024-2025 | Inspire |
| Kestra Medical Technology Services, INC. | $54.69 | 2024 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $53.89 | 2022-2023 | Camzyos |
| Boston Scientific Corporation | $53.33 | 2021-2025 | Watchman, Watchman Flx |
| Merck Sharp & Dohme LLC | $49.88 | 2023-2025 | Verquvo, Capvaxive |
| Lilly USA, LLC | $42.01 | 2023-2024 | Mounjaro |
| Novo Nordisk INC | $41.23 | 2024-2025 | Ozempic, Rybelsus |
| Alnylam Pharmaceuticals INC. | $28.89 | 2025 | Onpattro |
| Lexicon Pharmaceuticals, INC. | $19.21 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $18.49 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $18.23 | 2024 | Evkeeza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.19 | 2022 | |
| Amgen INC. | $16.74 | 2025 | Repatha |
| Bridgebio Pharma, INC. | $15.13 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Strobel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.